平安健康上線“慢病用藥需求登記平台”，助力保障居民用藥需求
受上海疫情影響，目前很多家庭購買常用藥的需求難以滿足。特別是不少慢病患者，家中的藥品出現了斷檔，對於疾病的控制與治療造成了較大影響。
在這特殊時刻，平安健康醫療科技有限公司(股票簡稱“平安好醫生”，1833.HK)發揮自身平台優勢資源整合能力，聯合上海全市200餘家目前尚在營業中的本地藥房，即日起上線“慢病用藥需求登記平台”，鏈接本地藥店與有需求的本地居民，為用户尋找急需藥品，使“疫時”本地購藥信息更及時、透明，助力保障居民用藥需求。
有慢病用藥需求的用户登錄平安健康APP或掃描海報二維碼，通過官方“慢病用藥需求登記平台”填寫需求信息。針對當前疫情防控形式，平安健康嚴格遵守當地各項防疫措施，用户進入“慢病用藥需求登記平台”頁面後，可實時查詢周邊營業藥房，自主進行線上找店、購藥，慢病用藥需求登記。平安健康將根據用户登記的用藥需求盡力協調相關資源幫助用户尋藥。此外，有常用藥品需求的用户亦可通過該頁面在平安健康大藥房店鋪下單，一定程度緩解當下購藥難題。
除了上線“慢病用藥需求登記平台”，在此輪抗疫行動中，平安健康還積極響應政府抗疫號召，充分履行自身企業責任，發揮醫療資源優勢，調動國大藥房、雷允上藥房等長期供應商資源，多次為上海徐匯、浦東等區域捐贈短缺藥品及各類防疫物資；在香港和吉林抗擊疫情的過程中，平安健康也積極承擔社會責任，協同平安集團內多家子公司多方協調，從多地採購醫用防護服口罩、醫用手套、免洗手消毒液等防疫物資，第一時間運送抵香港及長春市。
在防疫關鍵時刻，此次快速響應政府及大眾需求的背後，是平安健康長久以來持續打造的線下醫療網絡及供應商管理體系。截至2021年12月31日，平安健康合作藥店數達20.2萬家，佈局超225箇中心倉，不斷升級藥品服務能力，擴展中心倉物流網絡，為各相關方提升零售業務效率和規模。同時，平安健康持續深耕融合“HMO健康管理+家庭醫生會員制+O2O醫療服務”的整體商業模式，積極發揮線上線下醫療健康服務網絡優勢，精準匹配用户需求，為用户提供“省心、省時、省錢”的醫療健康服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
